Therapeutic Advances in Neurological Disorders (Aug 2021)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

  • Heinz Wiendl,
  • Ralf Gold,
  • Thomas Berger,
  • Tobias Derfuss,
  • Ralf Linker,
  • Mathias Mäurer,
  • Orhan Aktas,
  • Karl Baum,
  • Martin Berghoff,
  • Stefan Bittner,
  • Andrew Chan,
  • Adam Czaplinski,
  • Florian Deisenhammer,
  • Franziska Di Pauli,
  • Renaud Du Pasquier,
  • Christian Enzinger,
  • Elisabeth Fertl,
  • Achim Gass,
  • Klaus Gehring,
  • Claudio Gobbi,
  • Norbert Goebels,
  • Michael Guger,
  • Aiden Haghikia,
  • Hans-Peter Hartung,
  • Fedor Heidenreich,
  • Olaf Hoffmann,
  • Boris Kallmann,
  • Christoph Kleinschnitz,
  • Luisa Klotz,
  • Verena I. Leussink,
  • Fritz Leutmezer,
  • Volker Limmroth,
  • Jan D. Lünemann,
  • Andreas Lutterotti,
  • Sven G. Meuth,
  • Uta Meyding-Lamadé,
  • Michael Platten,
  • Peter Rieckmann,
  • Stephan Schmidt,
  • Hayrettin Tumani,
  • Frank Weber,
  • Martin S. Weber,
  • Uwe K. Zettl,
  • Tjalf Ziemssen,
  • Frauke Zipp,

DOI
https://doi.org/10.1177/17562864211039648
Journal volume & issue
Vol. 14

Abstract

Read online

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).